Merck (MRK) Stock May Be 38% Undervalued Following Melanoma Vaccine Results

Merck has delivered a powerful multi year share price run and a packed oncology news flow, which naturally raises a simple question for you as an investor. Is the current US$145.27 price broadly in line with what the business can generate in cash over time, or is the market leaning too hard on the story around its pipeline and partnerships?

• Over the past 5 years Merck has returned 92.3%, putting a lot of long term optimism into the stock and making the link between that gain and the strength of its cash flows more important to scrutinize.
• Positive late stage cancer data, fresh regulatory approvals for Keytruda combinations and heavy investment in new facilities may support expectations for future cash generation while also pulling forward some spending and execution risk into the near term.
• If you'd rather focus on earnings, this one's for you. See why Merck's 113.0x P/E tells a different valuation story.

The stock's next move may depend on whether that recent price level lines up with the intrinsic value suggested by its cash flows under a Discounted Cash Flow (DCF) view.

To compare Merck's cancer pipeline and cash flow story with other potential opportunities in the market, evaluate it alongside companies in the 34 healthcare AI stocks.

Is Merck a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) approach links Merck's value to the cash it can return to shareholders over time. On this model, the business is treated as a mature cash generator with ongoing growth rather than a turnaround or shrinking operation, with latest twelve month free cash flow of about $16.1b and projections that rise into the mid 2030s.

That matters for you because the DCF output, built from those rising cash flow estimates, sits substantially above the current $145.27 share price. The recent Phase 3 melanoma vaccine success with Moderna, along with other oncology data, helps explain why the market is willing to pay up for Merck, yet the cash flow model still suggests a richer stream of value than the price fully reflects. Find out what Merck could be worth using our Discounted Cash Flow (DCF) estimate.

The Merck Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Merck pick up where this valuation puzzle leaves you by spelling out which paths for Merck's growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price on the Community page. Each scenario links a fair value estimate to a clear storyline around the key drivers and pressure points, so you can watch over time which version of events seems to be taking shape.

Merck’s community split comes down to whether a broad late stage pipeline outweighs execution risk around KEYTRUDA’s eventual loss of exclusivity.

Bull case: 7% undervalued

"Merck plans to bring over 20 new growth drivers to market in the coming years, and management now points to more than US$70b in non risk adjusted mid 2030s revenue potential…"

Discover why this Narrative puts Merck at 7% undervalued.

Bear case: 20% overvalued

"The numbers implied by Merck’s current valuation and guidance, including mid 2030s non risk adjusted revenue ambitions of more than US$70b from new human health products, suggest the share price already reflects a high degree of confidence…"

Explore why this Narrative puts Merck at 20% overvalued.

Merck’s valuation is only part of the story

Before you anchor on any price or cash flow model for Merck, it is worth knowing that our broader checks have flagged specific concerns that call for closer inspection on your side. Take a closer look at 5 warning signs before settling on a valuation.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com